52X Stock Overview
Operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Magle Chemoswed Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.96 |
| 52 Week High | SEK 4.06 |
| 52 Week Low | SEK 1.96 |
| Beta | 0.56 |
| 1 Month Change | 6.47% |
| 3 Month Change | 1.37% |
| 1 Year Change | 33.33% |
| 3 Year Change | 5.34% |
| 5 Year Change | n/a |
| Change since IPO | 35.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 52X | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 6.5% | 4.5% | 1.2% |
| 1Y | 33.3% | 1.2% | 10.1% |
Return vs Industry: 52X exceeded the German Life Sciences industry which returned 1.2% over the past year.
Return vs Market: 52X exceeded the German Market which returned 10.1% over the past year.
Price Volatility
| 52X volatility | |
|---|---|
| 52X Average Weekly Movement | 8.1% |
| Life Sciences Industry Average Movement | 7.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 52X's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 52X's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1944 | 147 | Justin Pierce | www.maglechemoswed.com |
Magle Chemoswed Holding AB (publ), together with its subsidiaries, operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; amantadine sulfate that is used in the treatment of central nervous system disorders; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease. The company also offers EmboCept S, a microsphere-based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company’s microsphere technology; and SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures.
Magle Chemoswed Holding AB (publ) Fundamentals Summary
| 52X fundamental statistics | |
|---|---|
| Market cap | €59.92m |
| Earnings (TTM) | €1.46m |
| Revenue (TTM) | €18.21m |
41.1x
P/E Ratio3.3x
P/S RatioIs 52X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 52X income statement (TTM) | |
|---|---|
| Revenue | SEK 209.21m |
| Cost of Revenue | SEK 25.74m |
| Gross Profit | SEK 183.48m |
| Other Expenses | SEK 166.73m |
| Earnings | SEK 16.75m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | 0.91 |
| Gross Margin | 87.70% |
| Net Profit Margin | 8.00% |
| Debt/Equity Ratio | 25.4% |
How did 52X perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 02:37 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Magle Chemoswed Holding AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin Sule | Redeye |